NASDAQ:CDMO - Avid Bioservices Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.62 +0.31 (+7.19 %)
(As of 04/23/2019 04:00 PM ET)
Previous Close$4.31
Today's Range$4.33 - $4.67
52-Week Range$3.05 - $8.44
Volume181,900 shs
Average Volume247,540 shs
Market Capitalization$259.07 million
P/E RatioN/A
Dividend YieldN/A
Beta2.62
Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.

Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDMO
CUSIPN/A
Phone714-508-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.62 million
Book Value$1.00 per share

Profitability

Net Income$-21,810,000.00

Miscellaneous

Employees185
Market Cap$259.07 million
Next Earnings Date7/15/2019 (Estimated)
OptionableOptionable

Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Shares of Avid Bioservices reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices Inc (NASDAQ:CDMO) released its quarterly earnings data on Monday, March, 11th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.07) by $0.02. The biopharmaceutical company earned $13.78 million during the quarter, compared to analysts' expectations of $13.43 million. Avid Bioservices had a negative return on equity of 20.74% and a negative net margin of 3.52%. View Avid Bioservices' Earnings History.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release their next quarterly earnings announcement on Monday, July 15th 2019. View Earnings Estimates for Avid Bioservices.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices issued an update on its FY 2019 earnings guidance on Monday, March, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $51-52.5 million, compared to the consensus revenue estimate of $52.8 million.

What price target have analysts set for CDMO?

2 analysts have issued 12 month target prices for Avid Bioservices' shares. Their forecasts range from $10.00 to $11.00. On average, they expect Avid Bioservices' stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 127.3% from the stock's current price. View Analyst Price Targets for Avid Bioservices.

What is the consensus analysts' recommendation for Avid Bioservices?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avid Bioservices.

Has Avid Bioservices been receiving favorable news coverage?

Headlines about CDMO stock have been trending positive this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avid Bioservices earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days.

Are investors shorting Avid Bioservices?

Avid Bioservices saw a decline in short interest during the month of March. As of March 15th, there was short interest totalling 1,686,938 shares, a decline of 23.8% from the February 28th total of 2,213,262 shares. Based on an average trading volume of 349,324 shares, the short-interest ratio is currently 4.8 days. Approximately 3.1% of the company's shares are sold short. View Avid Bioservices' Current Options Chain.

Who are some of Avid Bioservices' key competitors?

What other stocks do shareholders of Avid Bioservices own?

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the folowing people:
  • Dr. Roger J. Lias, Pres, CEO & Director (Age 59)
  • Mr. Mark R. Ziebell, VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Mr. Daniel R. Hart, Chief Financial Officer (Age 46)
  • Mr. Stephen Michael Hedberg, Sr. Director of Fin. & SEC Reporting and Principal Financial & Accounting Officer (Age 44)
  • Ms. Lorna Larson, Sr. Director of HR

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Roubaix Capital LLC (0.87%), Legato Capital Management LLC (0.71%), Meeder Asset Management Inc. (0.03%), Harborview Advisors LLC (0.02%) and Valeo Financial Advisors LLC (0.01%). Company insiders that own Avid Bioservices stock include Joel Mccomb and Mark R Bamforth. View Institutional Ownership Trends for Avid Bioservices.

Which major investors are buying Avid Bioservices stock?

CDMO stock was purchased by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, Legato Capital Management LLC, Harborview Advisors LLC, Valeo Financial Advisors LLC and Meeder Asset Management Inc.. View Insider Buying and Selling for Avid Bioservices.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $4.62.

How big of a company is Avid Bioservices?

Avid Bioservices has a market capitalization of $259.07 million and generates $53.62 million in revenue each year. The biopharmaceutical company earns $-21,810,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Avid Bioservices employs 185 workers across the globe.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is http://www.avidbio.com.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]


MarketBeat Community Rating for Avid Bioservices (NASDAQ CDMO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  477
MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel